If it weren’t for bad luck, Gilead Sciences (NASDAQ:GILD) might not have any luck at all.
At least it might seem that way lately for the biotech’s shareholders. There has been plenty of bad news with Gilead’s announcements in recent months. When will Gilead Sciences’ unlucky streak end?
